Talk about a solid performer. Here it is SYBD. I have watched this stock off and on since it was .32 and never bought because I always thought it was going to pullback but it continues to go north and I'm still watching.



Web Site
: : Oxygen Biotherapeutics, Inc : :

Investors Website Area
: : Oxygen Biotherapeutics, Inc : :



About Synthetic Blood International

Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development an oxygen therapeutic/blood substitute and a liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit : : Oxygen Biotherapeutics, Inc : :.







Latest News:

Tue, Feb 26, 2008

4:00 AM Synthetic Blood Announces Department of Defense Grant for Traumatic Brain Injury Clinical Trial with Oxycyte - Business Wire

QuoteMedia - News

I got carried away with a couple of others and waited too long this morning. I just got in here for 500 shares @ .70

Just my opinion but this looks as solid as any penny play I have found.

If there is a pullback I'm going in heavy here and if not I'm still going to add some today and tomorrow. I may even sell some tdcp to add SYBD.

Watching this one very closely. Good things to come (IMO)

Sure has had strong PPS performance lately, I'm in!

__________________
Disclaimer: Any stocks I comment on are my opinion only. Play the stock market at your own risk!
My Bottom Plays: EVERYTHING!
SMC - THE BEST STOCK MARKET FORUM
FREE LIVE CHAT if you join Stock Market Cats
"A government big enough to give you everything you need, is big enough to take everything you have." - Thomas Jefferson

Welcome aboard!!! I really...really like this stock I just wish I had moved on it earlier.

It always seems I'm too early or too late but in this case I think we are good.

I sold out of 3 plays in hopes of a pullback today or tommorrow to add but either way I'm going to load up more

A little info on SYBD:

Synthetic Blood International, Inc. (OTC BB: SYBD) is a cutting edge biomedical product development company specializing in creating innovative pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, liquid ventilation and implanted glucose sensing. Once these sophisticated products reach the market, they promise to revolutionize treatment of such disease states as diabetes, acute respiratory distress syndrome, stroke, myocardial infarction, and many malignant tumors.

Many of Synthetic Blood's technology platforms are based on the pioneering research of Dr. Leland Clark, developer of the first heart-lung machine and the Clark oxygen and glucose biosensor electrodes.

Backed by a team of industry-experienced scientists and product development engineers, clinicians, regulatory affairs specialists, and manufacturing and marketing experts, Synthetic Blood is vigorously pursuing strategic alliances with major pharmaceutical and medical device companies to market their products worldwide and to identify additional product opportunities in biomedical, commercial and industrial markets.
**************************************************

LATEST NEWS RELEASES:

http://phx.corporate-ir.net/phoenix....20&p=irol-news

**************************************************

Products, Technologies, Clinical Solutions

Product development at SYBD is taking place on several innovative technological platforms:

Fluorovent, a proprietary oxygen-carrying fluorocarbon, is a highly effective medium for gas exchange. It is effective in increasing pulmonary function and the diffusion of oxygen and carbon dioxide in cases of respiratory distress.

Oxycyte is an oxygen-carrying intravenous emulsion that can carry five times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carbon dioxide to the lungs for disposal. New applications of oxygen therapeutic agents include stroke, myocardial infarction, and certain malignant diseases.

The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. The most accurate glucose monitor available, SYBD's implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.

Based on studies to date, all SYBD products offer significant competitive advantages:

Fluorovent:


longer pulmonary retention, reducing need for replacing exhaled fluid
potentially less costly, less labor intensive
environmentally safe - no bromine or chlorine
does not cause hyperinflated, non-collapsible lung syndrome



Oxycyte:


slower exhalation rate results in longer effective blood circulation half-life
environmentally safe - no bromine or chlorine
no potential for hyperinflated, non-collapsible lung condition



Implanted Glucose Biosensor:


significantly more accurate in glucose range of 30-500 mg/dl
accurate to an oxygen saturation as low as 2%
extended implant life with stable, linear response
fully implanted; completely non-invasive after implant
eliminates patient compliance factor in achieving tight glucose control

Have bid in for 4500 @ .63

Filled so now I'm waiting to see where this goes tomorrow before finishing it off with 5k more.

BAMMMMMMMMMM !!!!!!!!!!!!!!!!!!!!!!!!!!!!

AFTER HOURS NEWS!!!!!!!!!!!!!!!!!!!


Office of Naval Research Provides $3.5 Million in New Grants for Clinical Research Involving Synthetic Blood International's Oxycyte(R)
Thursday March 6, 4:05 pm ET

COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD - News) announced today that Virginia Commonwealth University Reanimation Engineering Shock Center (VCURES) has received four separate research grants from the Office of Naval Research (ONR) totaling $3,517,696. These four grants will support pre-clinical research studies involving Oxycyte®, a product of Synthetic Blood International. Oxycyte is the company’s perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.
ADVERTISEMENT


Bruce Spiess, M.D., Virginia Commonwealth University Professor of Anesthesiology and Emergency Medicine, Director of Research (Anesthesiology) and Director of VCURES said, “These grants will allow us to expand upon the previous studies which showed that early intervention with Oxycyte can prevent the destruction of nerve cells, brain tissue in a number of conditions including decompression illness and gas embolism.”

Approximately $1.2 million (over 3 years) will be utilized in ongoing studies of perfluorocarbon emulsions in the treatment of severe decompression sickness (DCS). DCS occurs in dive accidents, mine workers, high altitude and space flight, and is a potential complication of rescue from a disabled submarine (DISSUB). This grant supports on-going work at VCURES which has demonstrated Oxycyte’s significantly improved oxygen delivery to tissues and increased removal of nitrogen from the body in past experiments.

A $1.6 million grant (over 3 years) was made for support of research into Oxycyte’s ability to treat/prevent organ damage from arterial gas embolism (AGE). AGE is a potential result of DCS but also occurs during a number of surgical procedures including cardiac surgery, orthopedic-joint replacement, gynecologic surgery, and neurosurgery.

A $300,000 dollar grant (over two years) was made to sponsor a post-doctoral candidate to work in the microcirculation laboratories of VCURES supporting research in AGE, DCS, as well as other work in traumatic brain injury (TBI). This support will extend the effectiveness of other PhD personnel already involved in basic science investigations of critical oxygen delivery to tissues with and without the presence of Oxycyte.

The fourth grant was for approximately $300,000 to develop pilot studies into the effectiveness of Oxycyte in treating traumatic brain injury secondary to a blast. Blast injury is the largest single cause of mortality and long term morbidity for coalition troops stationed in Iraq and Afghanistan. The VCURES work in blast injury will carefully dovetail with other Oxycyte research in TBI. Prior work from VCURES has shown PFC to be effective in treating TBI from isolated blunt closed head injury and blast, as a mechanism for brain injury, may well have similarities as well as differences from isolated blunt contusive brain injury. The goals of the researchers are to not only investigate the basic science but also to rapidly transition any medical advantages to the troops as soon as possible. Data from all four of these grants will provide basic science backing to other potential applications for this unique oxygen therapeutic in acute critical illness. These four grants together demonstrate the commitment that the DOD and ONR has to finding solutions to combat casualty care as well as interest in the third generation PFC – Oxycyte.

“These grants to VCURES following the announcement last week of a $1.9 million grant from the Department of Defense to further study Oxycyte in treating traumatic brain injury are a strong indication that the military sees the potential benefits of Oxycyte in preventing or arresting brain damage,” said Robert Larsen, president and CEO of Synthetic Blood, International. “We are hopeful that these additional funds will lead to results that can speed us on the road to approval by the FDA.”

Said Dr. Spiess, who also is the co-chairman of Synthetic Blood’s Scientific Advisory Board, “We’re eager to put these funds to work to help lead to treatments that improve patient outcomes in these critical areas.”

Synthetic Blood International plans to begin a Phase IIb trial of Oxycyte in 200 TBI patients in the second quarter of this year.

Sweet....it's a first step!

__________________
Disclaimer: Any stocks I comment on are my opinion only. Play the stock market at your own risk!
My Bottom Plays: EVERYTHING!
SMC - THE BEST STOCK MARKET FORUM
FREE LIVE CHAT if you join Stock Market Cats
"A government big enough to give you everything you need, is big enough to take everything you have." - Thomas Jefferson